IGBA CEO Advisory Committee
"During COVID-19, generics companies worked together to help ensure reliable access to essential medicine for people across the world. The creation of, and our participation in, the IGBA CEO Advisory Committee, is our commitment that we will act with patients in mind as we work together on global solutions for accessible and sustainable healthcare."
"Generic and biosimilar medicines are a cornerstone for improving global quality of life and well-being. We here are united in our commitment to improve patients access to cost effective therapies that are quality-assured and safe."
"A passion for helping patients access more affordable essential medicines has been the catalyst for so many healthcare innovations. Whether driving the ongoing success of the global generics industry or supporting the rise of biosimilars, it is unity, alignment, and partnership that will enable us to continue making a positive impact on patients' lives. I look forward to serving on IGBA's inaugural CEO Advisory Committee and working alongside my esteemed industry colleagues to help shape the global discussions and policies critical for accelerating even more innovation, access, and affordability."
"We are always stronger when we work together. This advisory committee provides a valuable opportunity to address some of the most important challenges ahead as we seek to secure a sustainable future for patient access to affordable medicines around the world."
"I am glad to be a part of the transformative IGBA advisory board with my fellow colleagues from across the healthcare industry. As the world continues to face healthcare challenges, I firmly believe this platform will bring pivotal issues to the fore and serve as a collective force towards addressing critical healthcare needs."
"Driving accessibility to state-of-the-art medicines and further advancing the medical off-patent sector is a strong and important mission that connects. It is about making a difference in medical treatment worldwide, consequently caring for the lives of patients. There is great strength in a unified approach and the IGBA CEO Advisory Committee offers exactly that opportunity. Global challenges require global solutions. Generic and biosimilar medicines will be levers towards advancing patient care."
"Having one and united voice is always great news in our industry. Together we will contribute to focus on the healthcare system sustainability and, of course, on the improvement patient access to costly treatments."
"Polpharma Group and myself take our purpose to help people to live a healthy life in a healthy world very serious. We focus on the patient to give better access to affordable drug treatments and to support important topics like compliance and other aspects of healthcare with digital and other innovative solutions. As part of the IGBA CEO Advisory Committee I will focus to contribute strongly in these areas."
"Improving access to medicines is a global challenge that requires global action. That is why I look forward to working closely as a trusted partner with organizations including the WHO and WTO as an inaugural member of the CEO Advisory Committee established by the IGBA."
"I am happy to join the CEO Advisory Committee set up by the IGBA. The generic & biosimilar industry leaders of 14 leading multinational companies coming together for the first time to discuss critical global healthcare policy issues is a great step."
President and Chief Executive Officer
Member of the Board of Directors
"Accelerating patient access to high-quality medicines is our industry's common purpose and improving the lives of patients is Teva's unique mission so I'm pleased to join this CEO Advisory Committee to address global healthcare policy."
"This advisory committee represents a milestone for the 14 worldwide leading companies of generic, value added and biosimilar medicines, as for the first time we are officially together on facing the main actual challenges and we are all working by our common purpose: the patients."
"Patients everywhere rely on the companies represented by IGBA to access the medicines they need. I am happy to join the CEO Advisory Committee to continue to advance policy dialogue that drives towards new solutions for more equitable access for patients worldwide."
"The coming together of generic and biosimilar industry leaders in this forum is a great leap forward and one that will unite us all in a larger purpose to unlock newer possibilities that can impact and improve the quality of life for the patients. I see the convergence as a positive step that will open up discussions on how we can empower patients by making affordable therapies accessible to them. I look forward to contributing to this mission as an inaugural member of the CEO Advisory Committee of IGBA."